Impact of Pseudomonas and Staphylococcus Infection on Inflammation and Clinical Status in Young Children with Cystic Fibrosis
Objective
To assess the effects of Pseudomonas aeruginosa and Staphylococcus aureus infection on lower airway inflammation and clinical status in young children with cystic fibrosis (CF).
Study design
We studied 111 children age < 6 years who had 2 P aeruginosa–positive oropharyngeal cultures within 12 months. We examined bronchoalveolar lavage fluid (BALF) inflammatory markers (ie, cell count, differential, interleukin [IL]-8, IL-6, neutrophil elastase), CF-related bacterial pathogens, exotoxin A serology, and clinical indicators of disease severity.
Results
Young children with CF with both upper and lower airway P aeruginosa infection had higher neutrophil counts, higher IL-8 and free neutrophil elastase levels, increased likelihood of positive exotoxin A titers, and lower Shwachman scores compared with those with positive upper airway cultures only. S aureus was associated with increased lower airway inflammation, and the presence of both P aeruginosa and S aureus had an additive effect on concentrations of lower airway inflammatory markers. BALF markers of inflammation were increased with the number of different bacterial pathogens detected.
Conclusions
Young children with CF who have upper and lower airway P aeruginosa infection have increased endobronchial inflammation and poorer clinical status compared with those with only upper airway P aeruginosa infection. The independent and additive effects of S aureus on inflammation support the significance of polymicrobial infection in early CF lung disease.
Abbreviations: BAL, Bronchoalveolar lavage, BALF, Bronchoalveolar lavage fluid, CF, Cystic fibrosis, CFF-TDN, Cystic Fibrosis Foundation Therapeutics Development Network, IL, Interleukin, OP, Oropharyngeal
To access this article, please choose from the options below
Supported by grants from the National Institutes of Health (1 RO1 DK 57755-01, -02, K23 RR018611-05, and U01 HL081335-01), US Food and Drug Administration (FD-R-001695-01), Cystic Fibrosis Foundation Therapeutics Development Center Network, Novartis Corporation, and General Clinical Research Centers Program, National Center for Research Resources (MO1-RR00037, RR00046, RR00052, RR00064, RR00069, RR00070, RR00080, RR00188, RR02172, and RR08084). The authors declare no conflicts of interest.
PII: S0022-3476(08)00677-X
doi:10.1016/j.jpeds.2008.08.001
© 2009 Mosby, Inc. All rights reserved.
Refers to article:
- Infection, Inflammation, and the Downward Spiral of Cystic Fibrosis Lung Disease
